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costs or total RA-related costs between patients starting rituximab, abatacept, or 
inﬂiximab. From a U.S. commercial payer perspective the costs associated with the 
three infused RA-biologics are similar.
PMS19
REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN AND 
CHRONIC LOW BACK PAIN: TREATMENT PATTERN, DIRECT AND 
INDIRECT COSTS
Ivanova JI1, Birnbaum HG2, Kantor E2, Schiller M2, Johnstone B3, Faries D3, Risser R3, 
Swindle R3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Eli Lilly 
and Company, Indianapolis, IN, USA
OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for 
low back pain (LBP) and chronic LBP (CLBP). METHODS: There were 753 employees 
identiﬁed, ages 18 to 64 years, with ≥1 LBP diagnosis, per HEDIS speciﬁcations, and 
≥1 duloxetine prescription within a year after LBP diagnosis from a privately-insured 
claims database (2004–2007). Employees had continuous eligibility ≥6 months before 
(baseline) and ≥6 months after index duloxetine prescription (study period). Using 
propensity score matching, duloxetine-treated employees were matched to 753 LBP 
employees (controls) who initiated another pharmacological/non-invasive LBP treat-
ment in the same month from LBP diagnosis. A subset (n = 155 each) of matched 
employees with baseline CLBP (subsequent LBP diagnosis within 3–6 months after the 
initial LBP diagnosis) was also analyzed. McNemar tests were used to compare LBP 
treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and 
drug) and indirect (workloss) costs from third-party payer perspective. RESULTS: 
During the 6-month study period, duloxetine-treated employees versus controls had 
signiﬁcantly lower rates of other pharmacological therapy (e.g., 44.0% vs. 56.4% 
narcotic opioids; 29.5% vs. 40.9% NSAIDs; all p < .001) and non-invasive therapy 
(22.3% vs. 38.7% chiropractic therapy; 18.9% vs. 38.0% physical therapy; 14.2% vs. 
27.0% exercise therapy; all p < .001). Back surgery rate was lower among duloxetine-
treated employees compared with controls (1.7% vs. 2.8%, respectively; p = 0.157). 
Duloxetine-treated employees versus controls had signiﬁcantly lower 6-month indirect 
costs ($1723 vs. $2198, p = 0.004) and lower direct costs ($4935 vs. $5649, p = 0.267). 
Sensitivity analysis using multivariate analysis conﬁrmed the results. Among CLBP 
patients, duloxetine-treated employees versus controls had a lower rate of surgery 
(1.3% vs. 5.2%, p = 0.058), direct ($5519 vs. $7066, p = 0.345) and indirect costs 
($1996 vs. $2612, p = 0.191). CONCLUSIONS: Duloxetine treatment in LBP and 
CLBP employees versus other non-surgical treatment was numerically associated with 
reduced rates of non-surgical therapies, surgery, and lower direct and indirect costs.
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OBJECTIVES: To evaluate the cost effectiveness of febuoxstat compared with allo-
purinol for the management of chronic gout in the United States. METHODS: Using 
the FACT trial that compared febuoxstat with allopurinol in managing chronic gout, 
a “backward induction model” was designed using a hypothetical cohort of male 
patients in the US aged 40 to 80 years. Model estimates were taken from the trial and 
existing literature. The trial demonstrated equivalent efﬁcacy for these drugs but the 
probability of a patient attaining Allopurinol Hypersensitvity Syndrome (AHS) was 
inputted and evaluated. AHS probability and total costs were obtained from literature, 
and utility value was obtained from expert opinion. These values were used for the 
base case analysis. Using a societal perspective, QALYs and costs were calculated using 
backward induction to generate lifetime incremental cost effectiveness. All costs were 
reported as 2009 US dollars, after being inﬂated using the medical component of the 
CPI. Life expectancy, QALYs, and costs were discounted at a rate of 3%. RESULTS: 
Using a societal cost effectiveness threshold of US $150,000/QALY, managing chronic 
gout using febuoxstat daily is cost effective for males aged 55 to 75 years. It becomes 
cost ineffective for males aged 40 to 50 years. Febuoxstat contributed to greater 
QALYs for all patients with AHS at 2%. A one way sensitivity analysis was performed 
using the 55 year old male patient as a base case comparison with an ICER of US 
$110,701/QALY to test uncertainties. If AHS is not considered in this model, then 
febuoxstat will be to cost ineffective throughout this analysis. CONCLUSIONS: Cur-
rently, febuoxstat is more expensive, and since they are both equally efﬁcacious, 
allopurinol should be recommended as ﬁrst line therapy. Febuoxstat can be used as a 
cost effective alternative in certain age groups, if AHS occurs.
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OBJECTIVES: To determine the cost-effectiveness of Rituximab (Rituxan) in com-
parison to the standard treatment of Adalimunab (Humira) for patients with moderate 
to severe rheumatoid arthritis. METHODS: A decision analytic model was carried out 
comparing the effectiveness and treatment costs of two treatments consisting of the 
standard care (Adalimumab) or the alternative care (Rituximab). Four outcome groups 
were deﬁned for each alternative: Effective with or without adverse events and Not 
Effective with or without adverse events. Results from clinical trials and pertinent 
literature were used to derive the model inputs. A published equation was used to 
predict quality-adjusted life years (QALYs) from the Health Assessment Questionnaire 
(HAQ) disability index. The HAQ-DI assesses the extent of the patient’s functional 
ability and has been extensively used in clinical settings. The HAQ-DI is sensitive to 
change and is a good predictor of future disability and costs. Costs included the medi-
cation acquisition cost, the physician and monitoring costs as well as the average 
adverse drug events costs. All costs were expressed in 2009 US dollars. A sensitivity 
analysis was undertaken in order to assess the uncertainty surrounding calculated 
QALY scores. RESULTS: Based on the outcome estimates of the randomized clinical 
trials as well as the acquisition, physician, monitoring and adverse drug event costs. 
The study ﬁndings indicate that the clinical beneﬁts on the change in QALY scores 
resulting in an incremental cost of $66,123.00. The sensitivity analysis conﬁrmed the 
results to be robust and are not affected by uncertainty. CONCLUSIONS: This study 
suggests that Adalimumab is more costly and less effective than Rituximab. These 
results indicate that Rituximab should be utilized for the treatment of moderate to 
severe rheumatoid arthritis.
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OBJECTIVES: Fibromyalgia is a chronic condition manifesting with widespread pain, 
non-restorative sleep, fatigue and cognitive dysfunction. Fibromyalgia imposes high 
costs due to work loss and medical resource use. We built a decision-analytic model 
to assess the cost-effectiveness of treating severe ﬁbromyalgia with pregabalin. 
METHODS: Patients considered had Fibromyalgia Impact Questionnaire scores >59 
and pain scores >6.5 at baseline. Pregabalin 450 mg and 300 mg were compared to 
placebo, duloxetine, gabapentin, tramadol, milnacipran and amitriptyline. Patient 
response was assessed after 12 weeks of therapy: responders entered a long term model 
in which they maintained response, lost response, or dropped out. Response rates for 
pregabalin and placebo were derived from a pooled analysis of 3 randomized trials: 
response was deﬁned as a ≥30% improvement over baseline pain score and patient 
global impression of change rated much or very much improved. Response rates for 
other comparators were obtained from a systematic review of randomized controlled 
studies. Longer term outcomes were derived from an open-label follow-up extension 
of a randomised pregabalin study. The primary effectiveness endpoint was mean days 
in response. Resource use was estimated from published studies. Costs were calculated 
from a societal perspective including health care costs and productivity loss. RESULTS: 
At 12 weeks, people treated with pregabalin achieved 28 days in response compared 
to 14 with placebo. Total cost per patient was $402 higher with pregabalin 300 mg 
and $989 lower with pregabalin 450 mg compared to placebo. At 1 year, pregabalin 
300 mg was less costly and more effective than placebo, duloxetine, milnacipran or 
gabapentin: the incremental cost per additional day in response compared to tramadol 
and amitriptyline was $43 and $10 respectively. Pregabalin 450 mg gave reduced costs 
and more response days than all comparators. CONCLUSIONS: Pregabalin was 
found to be an effective therapy for severe ﬁbromyalgia patients and was cost-saving 
compared to most other ﬁbromyalgia treatments.
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OBJECTIVES: to perform economic evaluation of adalimumab + methotrexate vs 
rituximab + methotrexate and inﬂiximab + methotrexate in patients with rheumatoid 
arthritis resistant to traditional methods of treatment in Russian health care system. 
METHODS: the modeled study was performed. Data on dosing regimen, efﬁcacy and 
safety of biologics were extracted from studies ARMADA, DANCER, and ATTRACT. 
Effect was measured in proportion of patients receiving this combination achieved 
ACR 20/50/70. Cost of treatment with biologics combined with methotrexate for 24 
weeks and cost-effectiveness ratio (CER) were calculated from the Russian reimburse-
ment system point of view. RESULTS: adalimumab is more effective in patients 
achieved ACR 20 (67, 54, and 50% of patients receiving adalimumab, rituximab, and 
inﬂiximab accordingly achieved ACR 20), ACR 50 (55, 34, and 27% accordingly), 
and it is more effective that inﬂiximab and has nearly equal efﬁcacy with rituximab 
in patients achieved ACR 70 (27, 30, and 8% accordingly). The cost of treatment was 
682,229.06 rubles for adalimumab + methotrexate, 651,876.66 rubles for inﬂiximab 
+ methotrexate, and 472,906.20 rubles for rituximab + methotrexate. CER for effec-
tiveness criteria “achieving ACR 20” for adalimumab was 1,018,252.33. It was lower 
than for inﬂiximab (1,303,753.32), but higher than for rituximab (875,752.22). CER 
for effectiveness criteria “achieving ACR 50” was 1,240,416.47, 1,390,900.59, and 
2,414,358.00 accordingly, and CER for “achieving ACR 70” was 2,526,774.30, 
2,364,531.00, and 8,148,458.25 accordingly. Incremental CER for adalimumab was 
1,610,175.85 / 996,775.52 / 2,990,326.57 rubles for one patient achieved ACR 
20/50/70 compared to rituximab. CONCLUSIONS: adalimumab, used as ﬁrst line of 
therapy with biological drugs, is more economically effective in patients with rheu-
matoid arthritis resistant to standard therapy, than inﬂiximab. Rituximab seems to be 
